Trident Texofab Ltd

Trident Texofab Promoter Buying: ₹0.01 Cr

Promoter group trust Hardik Desai Family Trust bought 5,412 Trident Texofab shares on BSE. Promoter stake rose from 6.95% to 6.99%.

Value

₹0.01 Cr

Promoter stake change

+0.04%

Trident Texofab Promoter Buying

Hardik Desai Family Trust, a Promoter Group entity, bought 5,412 shares of Trident Texofab in the open market. Post-transaction holding rose to 6.99% of total equity.

Promoter stake change

+0.04%

Trident Texofab Annual General Meeting

Trident Texofab Limited has issued the notice for its 18th Annual General Meeting, scheduled for September 30, 2026, alongside its Annual Report for FY 2025-26.

Trident Texofab Other Announcement

Trident Texofab Limited has appointed M/s. PAAA & Associates as the Cost Auditor for the company, effective September 7, 2026.

Trident Texofab Board Meeting Outcome

Trident Texofab's board approved the Board's Report, called the 18th AGM for September 30, 2026, and appointed a cost auditor and scrutinizer.

Trident Texofab Credit Rating

CRISIL Ratings has withdrawn the credit rating for Trident Texofab Ltd. This action follows a recent review of the company's financial and operational standing.

Trident Texofab Credit Rating

Trident Texofab Limited has voluntarily withdrawn its credit ratings from CRISIL for bank facilities totaling Rs. 20 Crore. The ratings were reaffirmed at CRISIL B/Stable before withdrawal.

Value

₹20.00 Cr

Trident Texofab Q1 FY27 Results: Net Profit ₹0.5 Cr, Down 50.0% YoY

Trident Texofab Ltd reported revenue from operations of ₹26.1 Cr (-7.1% YoY) and net profit of ₹0.5 Cr (-50.0% YoY) for Q1 FY27.

Key figure

Net profit ₹0.5 Cr · -50.0% YoY

Trident Texofab Q4 FY26 Results: Net Loss of ₹2 Cr

Trident Texofab Ltd reported revenue from operations of ₹33.6 Cr (-12.0% YoY) and a net loss of ₹2 Cr for Q4 FY26.

Key figure

Net loss ₹2 Cr